Genzyme in the UK

Company Info


We recognise our responsibility for transparency in our working relationships with patient organisations, healthcare professionals and healthcare organisations.

Why is transparency important?

Collaboration between industry, healthcare professionals and healthcare organisations is a vital need in enabling the development and effective use of new medicines and shaping the future of research. Bringing greater transparency to these already well-regulated and legitimate relationships aims to build greater understanding of the collaboration between industry, healthcare professionals and healthcare organisations. We are committed to greater transparency in our industry and will continue to strive for the highest possible standards.

Why are we working with healthcare professionals, healthcare organisations and patient associations?

The healthcare professionals, healthcare organisations and patient associations with whom we work provide us with valuable, independent and expert knowledge derived from their clinical and disease management experience. We are dedicated to delivering a high quality service to patients who are at the centre of our business decisions. Collaborating with experts contributes significantly to our efforts to improve the quality of patient care, with benefits for individuals and society at large.

What is Sanofi Genzyme’s commitment in regards to transparency?

We believe that transparency reflects on credibility and engenders confidence in our company, and we are committed to complying with all applicable rules and regulations governing transparency.

Sanofi Genzyme abides by the rules of the Association of British Pharmaceutical Industry (ABPI) and the European Federation of Pharmaceutical Industries and Associations (EFPIA), and complies fully with the ABPI Code of Practice, and the Irish Pharmaceutical Healthcare Association (IPHA) code of practice concerning the support the company provides for patient organisations.

As of June 2016, Sanofi Genzyme is disclosing details of its collaborations with healthcare professionals and healthcare organisations. The disclosures include transfers of value made for activities such as educational grants to healthcare organisations as well as transfers of value to individual Healthcare Professionals such as sponsorship to attend educational meetings, speaker fees, consultancy activities and advisory boards. Transfers of value for research and development-related activities carried out by healthcare professionals and healthcare organisations for Sanofi Genzyme have been included in Sanofi’s disclosures.

Under both our obligations with the EFPIA Disclosure Code and ABPI Code of Practice, Sanofi Genzyme is listing all the transfers of value (payments which can be direct, indirect or in kind) made to healthcare organisations, patient associations, healthcare professionals from 2015 onwards.

In-line with the rest of the pharmaceutical industry, all transfers of value to healthcare organisations from 2015 will be held on the ABPI website and will no longer available on our website,

Our annual breakdown of transfers of value to patient associations for 2016 can be accessed through Sanofi’s UK website. For previous years visit our global website.

Date of preparation: March 2017

Contact Info:

Genzyme Therapeutics Ltd
4620 Kingsgate
Cascade Way
Oxford Business Park South
Tel: +01865 405200
Fax: +01865 774172

Contact Info:

Genzyme Ltd, Haverhill Operations
12 Rookwood Way
Tel: +01440 703522
Fax: +01440 716269